Eli Lilly and Co (LLY) Wins In Alimta Patent Case After Court Rules In Its Favor

Share on FacebookTweet about this on TwitterShare on Google+Share on RedditShare on LinkedInPrint this pageEmail this to someone

Eli Lilly and Co (NYSE:LLY) has won a patent case in respect of the company’s Alimta cancer drug in the federal court. The company filed a patent infringement case against the Israel-based Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)’s unit. Predictably, the Israeli firm expressed its disappointment over the judgment and disclosed that its options are open to appeal the case.

Patent Infringed

Eli Lilly and Co (NYSE:LLY) pointed out the court ruling saying that generic products planned by the unit of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) will infringe the patents of the American firm in relation to their blockbuster cancer drug, Alimta.

The patent covered the Alimta administration to patients with a vitamin regimen and provided the protection of intellectual property until May 2022. That offered the exclusivity for Alimta in the United States market until then. Therefore, there was no point in enabling generic competition in the next two years’ time when a separate patent expires.

Earlier, the court gave a ruling in March last year. According to that ruling, the court upheld the earlier validity of the vitamin regimen patent that Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) was ready to challenge.

Management Comments

Eli Lilly and Co (NYSE:LLY)’s SVP and general counsel, Michael Harrington, said that the company was pleased with the ruling of the District Court on its Alimta. He was also pleased that the court found that the vitamin regimen patent was infringed by Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).

The American firm’s SVP said that the company’s scientific research in support of the vitamin regimen patent warranted intellectual property protection. He said that the drug-maker will continue to stress the importance of protection of intellectual property rights as an important one to the biopharmaceutical industry, as well as, the patients that the industry serves. Eli Lilly and Co (NYSE:LLY) believes that the move would get the support for the next generation development of innovative medicines to unmet medical needs treatment.

Viraj Shah

Viraj Shah has completed M.Com (Finance) and is currently pursuing his CFP. He tracks US markets along with other global markets like India very closely. He is very passionate about stocks, real estate, and technology. He also believes that money can always be made in the market.

You may also like...

More in LLY
gavekal
Patterson Companies, Inc. (PDCO), Avery Dennison Corp (NYSE:AVY) and St. Jude Medical, Inc. (NYSE:STJ): Gavekal Capital, LLC’s Best 3 Fresh Buys

Gavekal Capital, LLC took the opportunity in 2Q2015 to remake its portfolio, offloading some stocks and initiating fresh positions, according...

Close